KAZIA THERAPEUTICS-SPON ADR (KZIA) Fundamental Analysis & Valuation

NASDAQ:KZIA • US48669G3039

8.25 USD
-0.26 (-3.06%)
Last: Mar 6, 2026, 08:00 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Forecast Earnings Financials Ownership News

This KZIA fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

Fundamental Rating

1

Taking everything into account, KZIA scores 1 out of 10 in our fundamental rating. KZIA was compared to 520 industry peers in the Biotechnology industry. Both the profitability and financial health of KZIA have multiple concerns. KZIA is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

0

1. KZIA Profitability Analysis

1.1 Basic Checks

  • KZIA had negative earnings in the past year.
  • In the past year KZIA has reported a negative cash flow from operations.
  • In the past 5 years KZIA always reported negative net income.
  • In the past 5 years KZIA always reported negative operating cash flow.
KZIA Yearly Net Income VS EBIT VS OCF VS FCFKZIA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -5M -10M -15M -20M -25M

1.2 Ratios

  • KZIA's Return On Assets of -158.60% is on the low side compared to the rest of the industry. KZIA is outperformed by 85.58% of its industry peers.
Industry RankSector Rank
ROA -158.6%
ROE N/A
ROIC N/A
ROA(3y)-179.5%
ROA(5y)-124.54%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
KZIA Yearly ROA, ROE, ROICKZIA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 200 -200 400 600

1.3 Margins

  • The Profit Margin and Operating Margin and Gross Margin are not available for KZIA so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
KZIA Yearly Profit, Operating, Gross MarginsKZIA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -200K -400K -600K -800K -1M

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

0

2. KZIA Health Analysis

2.1 Basic Checks

  • The number of shares outstanding for KZIA has been increased compared to 1 year ago.
  • KZIA has more shares outstanding than it did 5 years ago.
  • The debt/assets ratio for KZIA is higher compared to a year ago.
KZIA Yearly Shares OutstandingKZIA Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2M 4M 6M 8M
KZIA Yearly Total Debt VS Total AssetsKZIA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 10M 20M 30M 40M 50M

2.2 Solvency

  • Based on the Altman-Z score of -11.94, we must say that KZIA is in the distress zone and has some risk of bankruptcy.
  • KZIA has a Altman-Z score of -11.94. This is in the lower half of the industry: KZIA underperforms 76.54% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -11.94
ROIC/WACCN/A
WACCN/A
KZIA Yearly LT Debt VS Equity VS FCFKZIA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 20M -20M

2.3 Liquidity

  • KZIA has a Current Ratio of 0.21. This is a bad value and indicates that KZIA is not financially healthy enough and could expect problems in meeting its short term obligations.
  • KZIA's Current ratio of 0.21 is on the low side compared to the rest of the industry. KZIA is outperformed by 93.08% of its industry peers.
  • KZIA has a Quick Ratio of 0.21. This is a bad value and indicates that KZIA is not financially healthy enough and could expect problems in meeting its short term obligations.
  • KZIA has a worse Quick ratio (0.21) than 92.88% of its industry peers.
Industry RankSector Rank
Current Ratio 0.21
Quick Ratio 0.21
KZIA Yearly Current Assets VS Current LiabilitesKZIA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 10M 20M 30M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

5

3. KZIA Growth Analysis

3.1 Past

  • The Earnings Per Share has grown by an impressive 93.01% over the past year.
  • The Revenue for KZIA has decreased by -95.09% in the past year. This is quite bad
  • KZIA shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 11.58% yearly.
EPS 1Y (TTM)93.01%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%96.76%
Revenue 1Y (TTM)-95.09%
Revenue growth 3Y278.64%
Revenue growth 5Y11.58%
Sales Q2Q%-98.18%

3.2 Future

  • KZIA is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 15.14% yearly.
  • KZIA is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 372.34% yearly.
EPS Next Y79.58%
EPS Next 2Y35.4%
EPS Next 3Y22.59%
EPS Next 5Y15.14%
Revenue Next Year-25.37%
Revenue Next 2Y-32.53%
Revenue Next 3Y144.27%
Revenue Next 5Y372.34%

3.3 Evolution

  • The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
KZIA Yearly Revenue VS EstimatesKZIA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 200M 400M 600M
KZIA Yearly EPS VS EstimatesKZIA Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 0 -50 -100

More info and screens

Find the best growth stocksShow best growing peers

1

4. KZIA Valuation Analysis

4.1 Price/Earnings Ratio

  • KZIA reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Also next year KZIA is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
KZIA Price Earnings VS Forward Price EarningsKZIA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
KZIA Per share dataKZIA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.5 -1 -1.5 -2

4.3 Compensation for Growth

  • KZIA's earnings are expected to grow with 22.59% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y35.4%
EPS Next 3Y22.59%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. KZIA Dividend Analysis

5.1 Amount

  • KZIA does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

KZIA Fundamentals: All Metrics, Ratios and Statistics

KAZIA THERAPEUTICS-SPON ADR

NASDAQ:KZIA (3/6/2026, 8:00:02 PM)

8.25

-0.26 (-3.06%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-07
Earnings (Next)N/A
Inst Owners1.74%
Inst Owner Change1468.55%
Ins Owners1.39%
Ins Owner ChangeN/A
Market Cap93.52M
Revenue(TTM)114.00K
Net Income(TTM)-28.41M
Analysts82.5
Price Target19.38 (134.91%)
Short Float %2.18%
Short Ratio0.2
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)15.15%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)51.94%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 56.67
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-2.18
EYN/A
EPS(NY)-0.49
Fwd EYN/A
FCF(TTM)-0.73
FCFYN/A
OCF(TTM)-0.73
OCFYN/A
SpS0.15
BVpS-0.24
TBVpS-1.14
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -158.6%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-179.5%
ROA(5y)-124.54%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.13
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.21
Quick Ratio 0.21
Altman-Z -11.94
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)93.01%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%96.76%
EPS Next Y79.58%
EPS Next 2Y35.4%
EPS Next 3Y22.59%
EPS Next 5Y15.14%
Revenue 1Y (TTM)-95.09%
Revenue growth 3Y278.64%
Revenue growth 5Y11.58%
Sales Q2Q%-98.18%
Revenue Next Year-25.37%
Revenue Next 2Y-32.53%
Revenue Next 3Y144.27%
Revenue Next 5Y372.34%
EBIT growth 1Y-55.26%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y8.03%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y8.03%
OCF growth 3YN/A
OCF growth 5YN/A

KAZIA THERAPEUTICS-SPON ADR / KZIA FAQ

What is the fundamental rating for KZIA stock?

ChartMill assigns a fundamental rating of 1 / 10 to KZIA.


What is the valuation status for KZIA stock?

ChartMill assigns a valuation rating of 1 / 10 to KAZIA THERAPEUTICS-SPON ADR (KZIA). This can be considered as Overvalued.


Can you provide the profitability details for KAZIA THERAPEUTICS-SPON ADR?

KAZIA THERAPEUTICS-SPON ADR (KZIA) has a profitability rating of 0 / 10.


How financially healthy is KAZIA THERAPEUTICS-SPON ADR?

The financial health rating of KAZIA THERAPEUTICS-SPON ADR (KZIA) is 0 / 10.


What is the earnings growth outlook for KAZIA THERAPEUTICS-SPON ADR?

The Earnings per Share (EPS) of KAZIA THERAPEUTICS-SPON ADR (KZIA) is expected to grow by 79.58% in the next year.